Patients' Preferences for Adjuvant Sorafenib After Resection of Renal Cell Carcinoma in the SORCE Trial: What Makes It Worthwhile?
Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdx715
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2018
Authors
Publisher
Elsevier BV